| abstract |
The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity 5 of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib and the phenothiazine compound, trifluoperazine, or the phenothiazine compound, chlorpromazine, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib. In additional aspects, the invention 10 relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy. |